Human Serum Enzyme Overcomes Multiple Ultra-Rare Congenital Clotting Disorders

**OCR Number:** OCR 5775

**Description:**

- OCR 5775 is a therapeutic protein designed to overcome clotting defects:
  - it is resident to the circulatory system
  - has been purified and crystallized to ultra-high resolution
  - its activity is known to be triggered only at sites of platelet degranulation triggered under physiological conditions (i.e., response to vascular damage)
- As shown in the figure, weak aggregation is seen in the absence of OCR 5775 (blue curve) in a patient with a poorly characterized platelet storage disease. The addition of 50 nanomolar of OCR5775 (black curve) normalizes the clotting profile.
- This technology may also have utility in a critical care situation such as the Emergency Department for acute bleeding episodes (e.g., NSAID toxicity), first response, or military situations.

[Graph showing clotting profile with and without OCR 5775]

**Published/Issued Patents:** [PCT App. Pub. No. WO2013074615](#)

**Publications:**


**Licensing Contact:** David Lewin
david.lewin@yale.edu